Veterans Aging Cohort Study (VACS) 1.0 Index

ورودی‌های بالینی بیمار

حداقل ۱۸ — حداکثر ۱۲۰ • واحد: years

حداقل ۰ — حداکثر ۵۰۰۰ • واحد: cells/mm³

حداقل ۰ — حداکثر ۱۰۰۰۰۰۰۰ • واحد: copies/mL

حداقل ۳ — حداکثر ۲۵ • واحد: g/dL

حداقل ۰ — حداکثر ۵۰ • واحد: index

حداقل ۰ — حداکثر ۲۰۰ • واحد: mL/min/1.73m²

پنل نتیجه و تصمیم بالینی
در انتظار ورودی‌ها
vacs score
—points
آماده برای ارزیابی

پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.

طبقات خطر و بازه‌های امتیاز:
  • Low Risk0–20
  • Moderate Risk21–40
  • High Risk41–60
  • Very High Risk61–150
Direct Clinical Answer

The Veterans Aging Cohort Study (VACS) 1.0 Index calculates predicting invasive bacterial infection probability and quantifying systemic host response to sepsis. Key inputs include age. Scores guide administering empiric broad-spectrum antimicrobial regimens, infectious source control, and isolation protocols. This standardized assessment improves clinical decision safety and bedside patient management.

Clinical Guidelines & Evidence

Estimates 5-year all-cause mortality risk in patients with HIV and/or HCV by integrating HIV-specific biomarkers (CD4 count, HIV-1 RNA) with general health indicators (hemoglobin, liver function, kidney function, and hepatitis C co-infection).

Clinical Indication

The Veterans Aging Cohort Study (VACS) 1.0 Index is indicated for bedside clinical practice to support Estimates 5-year all-cause mortality risk in patients with HIV and/or HCV by integrating HIV-specific biomarkers (CD4 count, HIV-1 RNA) with general health indicators (hemoglobin, liver function, kidney function, and hepatitis C co-infection).. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

Target Population

Target population comprises Patients presenting with suspected sepsis, meningitis, pneumonia, COVID-19, opportunistic infections, or fever of unknown origin. Clinical application is indicated across Infectious disease services, septic shock bays, febrile illness clinics, and isolation units.

Limitations & Contraindications

Timely administration of empiric antibiotic therapy in suspected septic shock must never be delayed for score tabulation.

Clinical Pearls & Action Plan

Blood and site-specific microbiological cultures should be secured prior to administering broad-spectrum antimicrobials.

Formula & Variables:

VACS 1.0 Index = Age points + CD4 points + HIV RNA points + Hemoglobin points + FIB-4 points + eGFR points + HCV points Age: <50y=0, 50-64y=12, ≥65y=27 CD4: ≥500=0, 350-499=6, 200-349=6, 100-199=10, 50-99=28, <50=29 HIV RNA: <500=0, 500-99999=7, ≥100000=14 Hemoglobin: ≥14=0, 12-13.9=10, 10-11.9=22, <10=38 FIB-4: <1.45=0, 1.45-3.25=6, >3.25=25 eGFR: ≥60=0, 45-59.9=6, 30-44.9=8, <30=26 HCV: No=0, Yes=5

Input Parameters

NameTypeRequiredDescription
ageintegerYesPatient's age in years(years)
cd4_countintegerYesCD4+ T cell count(cells/mm³)
hiv_rna_copies_mlintegerYesHIV-1 RNA viral load(copies/mL)
hemoglobin_g_dlfloatYesHemoglobin level(g/dL)
fib4_indexfloatYesFIB-4 Index for liver fibrosis assessment (calculated using age, ALT, AST, and platelet count)(index)
egfr_ml_minfloatYesEstimated glomerular filtration rate (eGFR)(mL/min/1.73m²)
hepatitis_c_coinfectionstringYesHepatitis C co-infection status

Score Interpretation & Guidance

RangeStageDescription
0–20Low RiskLow 5-year mortality risk
21–40Moderate RiskModerate 5-year mortality risk
41–60High RiskHigh 5-year mortality risk
61–150Very High RiskVery high 5-year mortality risk

Evidence-Based References (EBM)

  • Justice AC, McGinnis KA, Skanderson M, et al. Towards a combined prognostic index for survival in HIV infection: the role of 'non-HIV' biomarkers. HIV Med. 2010;11(2):143-151.
  • Tate JP, Justice AC, Hughes MD, et al. An internationally generalizable risk index for mortality prediction in HIV-infected adults. AIDS. 2013;27(4):563-572.
  • Justice AC, Dombrowski E, Conigliaro J, et al. Veterans Aging Cohort Study (VACS): Overview and description. Med Care. 2006;44(8 Suppl 2):S13-24.

Related calculators